logo
StoneX Completes Acquisition of R.J. O'Brien, Becoming the Largest Non-Bank FCM in the United States and Enhancing Global Multi-Asset Capabilities

StoneX Completes Acquisition of R.J. O'Brien, Becoming the Largest Non-Bank FCM in the United States and Enhancing Global Multi-Asset Capabilities

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) — StoneX Group Inc. (NASDAQ: SNEX) ('StoneX' or the 'Company'), today announced the successful completion of its previously announced acquisition of R.J. O'Brien ('RJO'), the oldest independent futures brokerage in the United States. This transformative acquisition makes StoneX the largest non-bank Futures Commission Merchant ('FCM') in the U.S. and positions the company as a market leader in global derivatives.
Founded in 1914, RJO supports over 75,000 client accounts and serves the industry's largest global network of approximately 300 introducing brokers ('IBs'), as well as commercial and institutional clients, and individual investors. RJO brings an attractive financial profile to StoneX, having generated $766 million in revenue and approximately $170 million in EBITDA during calendar 2024.
As a combined company, StoneX provides clients with access to nearly every major global derivatives exchange, and offers one of the most comprehensive multi-asset platforms in the industry. RJO's clients can now access StoneX's extensive range of markets, products, and services, including an expansive over-the-counter ('OTC') hedging platform, physical commodity hedging, financing, and logistics services, as well as access to deep liquidity across fixed income products.
Through the integration of the two companies, StoneX has targeted significant revenue synergies via cross-sell opportunities in OTC derivatives, physical commodity trading, and fixed income products. StoneX has also targeted $50 million in expense savings and unlocking at least $50 million in capital synergies through operational consolidation. The acquisition, which expands StoneX's client float by nearly $6 billion, is expected to enhance StoneX's margins, return on equity and be accretive to earnings.
'This is a proud moment for both companies. With more than 200 years of combined futures and commodities expertise, we are strengthening StoneX's role as an integral part of the global financial infrastructure,'
said Sean O'Connor, Executive Vice-Chairman of StoneX.
'This acquisition creates an unmatched knowledge base and reinforces our position as the counterparty of choice for clients.'
Philip Smith, Chief Executive Officer of StoneX, added:
'This transaction significantly expands our scale and increases our capabilities in several critical areas, including through a materially expanded client network and the addition of the leading introducing broker business. The combination of the companies' leading technologies and tools, such as in OTC hedging, risk management, and trading execution and liquidity across multiple asset classes, will deliver clients important benefits. This transaction adds significant value for our clients and reinforces our ability to deliver across asset classes through every market cycle.'
Gerry Corcoran, Chairman and CEO of RJO, said:
'Today marks an exciting milestone as RJO joins StoneX to deliver broader services and greater reach to our clients. We will continue to deliver the same level of outstanding and personalized service we've always provided – now on an even larger scale with more extensive resources. We couldn't be more pleased about the cultural fit and strong client-first approach at StoneX that mirrors RJO's philosophy.'
Speaking on behalf of the O'Brien family, the majority shareholders in RJO, Board member John O'Brien, Jr. said:
'We are incredibly proud of our heritage in the futures industry spanning nearly 111 years, along with the clients we've served and the industry we helped grow. We are grateful for the thousands of employees who have met our clients' needs so faithfully for all these years. And now, as we embark on the next chapter of this amazing story, we are confident that StoneX will carry on the important legacy of both firms while building a leading multi-asset global organization for the future.'
About StoneX Group Inc.
StoneX Group Inc., through its subsidiaries, operates a global financial services network that connects companies, organizations, traders and investors to the global market ecosystem through a unique blend of digital platforms, end-to-end clearing and execution services, high touch service and deep expertise. The Company strives to be the one trusted partner for its clients, providing its network, product and services to allow them to pursue trading opportunities, manage their market risks, make investments and improve their business performance. A Fortune 50 company headquartered in New York City and listed on the Nasdaq Global Select Market (NASDAQ: SNEX), StoneX Group Inc. and its more than 4,700 employees serve more than 54,000 commercial, institutional, and global payments clients, and more than 260,000 self-directed/retail accounts, from more than 80 offices spread across six continents. Further information on the Company is available at
www.stonex.com
.
About R.J. O'Brien
Founded in 1914,
R.J. O'Brien & Associates
is one of the leading futures brokerage and clearing firms in the United States, serving more than 75,000 institutional, commercial and individual clients globally, in addition to a network of approximately 300 IBs. RJO services the industry's most expansive global network of IBs, a vast array of middle market firms and many of the world's largest financial, industrial and agricultural institutions. The firm offers state-of-the-art electronic trading and 24-hour trade execution on every major futures exchange worldwide. RJO received the FOW International Award for Non-Bank FCM of the Year for five consecutive years, and the firm and its UK affiliate have earned eight honors from the HFM Global publications (now With Intelligence) in recent years.
Press Inquiries:
stonex@cognitomedia.com
Investor Relations Inquiries:
Kevin.Murphy@stonex.com
Cautionary Note Regarding Forward-Looking Statements
Statements in this release that are not historical facts are 'forward-looking' statements and 'safe harbor statements' within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and/or uncertainties, including those described in StoneX's public filings with the Securities and Exchange Commission. Forward-looking statements are based on management's current expectations and assumptions and not on historical facts. Examples of these statements include, but are not limited to, statements about the benefits of the proposed acquisition of RJO, including expected synergies and future financial and operating results, the plans, objectives, expectations and intentions of StoneX after the acquisition, the expected timing to close the acquisition and the expected use of proceeds of any debt financing. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Therefore, we caution you against relying on any of these forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated in such forward-looking statements include the risks related to the proposed acquisition and the integration of RJO as well as the risks and other factors described in StoneX's periodic reports filed with the Securities and Exchange Commission. In providing forward-looking statements, StoneX is not undertaking any duty or obligation to update these statements publicly as a result of new information, future events or otherwise, except as required by law. If StoneX updates one or more forward-looking statements, no inference should be drawn that it will make additional updates with respect to those other forward-looking statements.
SNEX-G
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Theravance Biopharma Inc (TBPH) Q2 2025 Earnings Call Highlights: Strong Sales and Strategic ...
Theravance Biopharma Inc (TBPH) Q2 2025 Earnings Call Highlights: Strong Sales and Strategic ...

Yahoo

time8 minutes ago

  • Yahoo

Theravance Biopharma Inc (TBPH) Q2 2025 Earnings Call Highlights: Strong Sales and Strategic ...

Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Theravance Biopharma Inc (NASDAQ:TBPH) reported a strong quarter with net sales reaching approximately $66 million, driven by demand growth and favorable pricing. The company completed a $225 million sale of its remaining royalty interests in Trilogy to GSK, significantly strengthening its balance sheet. The phase 3 Cypress trial for amproloxetine is progressing well, with enrollment nearing completion and top-line data expected in six months. Theravance Biopharma Inc (NASDAQ:TBPH) ended the quarter with approximately $340 million in cash and no debt, maintaining a strong financial position. The company is on track to achieve significant milestones, including a potential $150 million from royalty Pharma over the next 18 months. Negative Points The company did not provide guidance on the formal launch timing for Upellry in China, as Beatrice is still finalizing the commercialization plan. There is uncertainty regarding the pricing strategy for amproloxetine, as it is still early to determine a specific price point. The company faces challenges in ensuring proper education for clinicians to make the best decisions for patient needs, particularly in specialty pharmacy channels. Theravance Biopharma Inc (NASDAQ:TBPH) expects to pay approximately $27 million in taxes related to the Trilogy royalty sale in the second half of the year. There is potential for pushback on amproloxetine pricing and reimbursement, given the presence of generics with less efficacy and clear side effects. Q & A Highlights Warning! GuruFocus has detected 7 Warning Signs with TBPH. Q: What factors contributed to the improved pull-through performance for Upellary this quarter? A: Rhonda Farnham, Chief Business Officer, explained that the improved pull-through was driven by the transition of volume to specialty pharmacy, which enhances pricing and persistency. The support patients receive in this channel improves fulfillment and persistency compared to conventional retail pharmacy. The company remains focused on providing options that best meet individual patient needs while educating clinicians to make informed decisions. Q: Can you provide an update on the outlook for Upellary's growth in China and the Cyprus trial enrollment? A: Rhonda Farnham stated that Beatrice is leading the commercialization efforts in China, and further details will be shared once their market plan is unveiled. Anya Miller, Head of Development, noted that the Cyprus trial's US versus ex-US enrollment is expected to mirror previous studies, with all data to be disclosed at the topline readout. A press release will be issued upon full enrollment of the open-label portion. Q: How is Theravance Biopharma approaching the pricing strategy for amproloxetine, and what are the considerations for reimbursement in the US? A: Rhonda Farnham mentioned that while it's early to finalize pricing, an analysis of recent rare neuro drug launches suggests an average price of approximately $380,000 per year. The company is actively engaging with payers to highlight the unmet need and the potential benefits of amproloxetine, focusing on its safety profile and durability of effect. Q: What are the expectations for SG&A expenses related to amproloxetine's commercialization, and how might they change post-data readout? A: Aziz Sala, Chief Financial Officer, indicated that SG&A expenses are expected to remain stable through the year, with some pre-launch activities already underway. Post-data readout, if positive, there will be an increase in SG&A spend, but it will be targeted and not excessively large, focusing on supporting the launch and marketing efforts. Q: Can you elaborate on the operating leverage observed in the collaboration revenue growth compared to Upellary's net sales increase? A: Aziz Sala explained that the collaboration revenue growth outpaced net sales growth due to cost reimbursements between the companies. While this quarter showed a significant gap, future quarters may not see the same level of disparity. However, profit margins are expected to continue improving as net sales grow. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.

Bank of America Securities Sticks to Its Buy Rating for Apple (AAPL)
Bank of America Securities Sticks to Its Buy Rating for Apple (AAPL)

Business Insider

time21 minutes ago

  • Business Insider

Bank of America Securities Sticks to Its Buy Rating for Apple (AAPL)

Bank of America Securities analyst Wamsi Mohan maintained a Buy rating on Apple yesterday and set a price target of $250.00. The company's shares closed yesterday at $229.65. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Mohan is a 5-star analyst with an average return of 13.2% and a 61.64% success rate. Mohan covers the Technology sector, focusing on stocks such as Apple, Seagate Tech, and International Business Machines. In addition to Bank of America Securities, Apple also received a Buy from Goldman Sachs's Mike Ng in a report issued on August 8. However, on August 7, DZ BANK AG maintained a Hold rating on Apple (NASDAQ: AAPL). The company has a one-year high of $260.10 and a one-year low of $169.21. Currently, Apple has an average volume of 56.07M. Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AAPL in relation to earlier this year. Most recently, in May 2025, Chris Kondo, the CAO of AAPL sold 4,486.00 shares for a total of $933,940.34.

Bank of America Securities Sticks to Its Buy Rating for Liquidia Technologies (LQDA)
Bank of America Securities Sticks to Its Buy Rating for Liquidia Technologies (LQDA)

Business Insider

time21 minutes ago

  • Business Insider

Bank of America Securities Sticks to Its Buy Rating for Liquidia Technologies (LQDA)

Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Liquidia Technologies yesterday and set a price target of $35.00. The company's shares closed yesterday at $24.10. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Gerberry covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical, Liquidia Technologies, and BioMarin Pharmaceutical. According to TipRanks, Gerberry has an average return of 2.5% and a 48.57% success rate on recommended stocks. In addition to Bank of America Securities, Liquidia Technologies also received a Buy from LifeSci Capital's Cory Jubinville, PhD in a report issued yesterday. However, on July 29, Oppenheimer maintained a Sell rating on Liquidia Technologies (NASDAQ: LQDA). Based on Liquidia Technologies' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $3.12 million and a GAAP net loss of $38.37 million. In comparison, last year the company earned a revenue of $2.97 million and had a GAAP net loss of $40.93 million

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store